R1	Has_qualifier Arg1:T2 Arg2:T3	
R2	Has_qualifier Arg1:T5 Arg2:T6	
R3	AND Arg1:T11 Arg2:T12	
R4	Has_value Arg1:T12 Arg2:T13	
R5	Subsumes Arg1:T17 Arg2:T18	
R6	Subsumes Arg1:T19 Arg2:T20	
*	OR T17 T19
R7	Has_value Arg1:T17 Arg2:T21	
R8	Subsumes Arg1:T16 Arg2:T17	
*	OR T8 T15 T14 T11 T10 T9 T16
R9	AND Arg1:T24 Arg2:T25	
R10	AND Arg1:T27 Arg2:T28	
T1	Condition 11 21	neuropathy
T2	Drug 51 60	analgesia
T3	Qualifier 23 32	Regularly
T4	Condition 75 87	chronic pain
T5	Condition 117 131	mental illness
T6	Qualifier 110 116	severe
T7	Drug 205 213	fibrates
T8	Condition 388 399	anaphylaxis
T9	Condition 401 417	facial swelling,
T10	Condition 418 429	severe rash
T11	Condition 431 442	muscle ache
T12	Measurement 456 477	serum creatine kinase
T13	Value 448 452	rise
T14	Condition 479 500	inflammatory myopathy
T15	Condition 502 516	rhabdomyolysis
T16	Condition 520 548	liver function abnormalities
T17	Measurement 550 572	aspartate transaminase
T18	Measurement 574 577	AST
T19	Measurement 582 602	alanine transaminase
T20	Measurement 604 607	ALT
T21	Value 609 651	greater than 3 times upper limit or normal
T23	Non-query-able 655 865	Side-effects taking longer than 2 weeks to develop (because in such participants much longer blocks of treatment would be required, if the present study is positive such studies will be planned for the future)*
T24	Condition 886 897	intolerance
T25	Drug 879 885	statin
T26	Drug 923 943	antiretroviral drugs
T27	Condition 964 975	intolerance
T28	Drug 957 963	statin
T29	Pregnancy_considerations 996 1022	Pregnant or breast feeding
T30	Non-query-able 1078 1151	In clinical judgement of study doctor, participant should not participate
T31	Non-query-able 1025 1075	Side effects taking longer than 2 weeks to present
